The Letermovir: New drug for prophylaxis and treatment in cytomegalovirus
Keywords:
ไซโตเมกะโลไวรัส; Letermovir, HSCT; การปลูกถ่ายอวัยวะAbstract
Cytomegalovirus (CMV) is a common virus that can cause serious complications in people with weakened immune systems, such as those who have undergone hematopoietic cell transplantation (HSCT) or organ transplantation. CMV can lead to pneumonia, urinary tract infections, brain infections, and organ rejection. Current CMV antiviral drugs, such as ganciclovir, valganciclovir, cidofovir, and foscarnet, work by inhibiting the activity of the CMV DNA polymerase enzyme, which prevents the virus from replicating. However, these drugs have significant side effects, including bone marrow suppression and nephrotoxicity. In 2017, the U.S. Food and Drug Administration (FDA) approved letermovir as a new CMV antiviral drug. Letermovir works by inhibiting the activity of the terminase complex, a protein essential for CMV replication. Letermovir is effective in reducing CMV infection after HSCT or organ transplantation, and it also reduces mortality in these patients. In addition, letermovir has the important advantage of not having bone marrow suppression or nephrotoxicity, so it does not increase the risk of complications in patients with weakened immune systems. Conclusion Letermovir is a new, effective, and safe option for CMV antiviral therapy in patients who have undergone HSCT or organ transplantation.
Key words: CMV, Letermovir, HSCT, organ Transplantation
References
PREVYMIS (Letermovir) Tablets and PREVYMIS (Letermovir) Injection [Internet]. U.S. Food and Drug Administration 2017 [cited 2018 Oct 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209939Orig1s000,209940Orig1s000TOC.cfm.
Prevymis Kenilworth (NJ) [Internet]. Merck Sharp & Dohme Corp 2023 [cited 2023 Dec 10]. Available from: https://www.merck.com/product/usa/pi_circulars/p/prevymis/prevymis_pi.pdf.
Kim ES. Letermovir: First Global Approval. Drugs. 2018;78(1):147-52.
Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017;377(25):2433-44.
Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013;13 Suppl 4:93-106.
Boeckh M. Current antiviral strategies for controlling cytomegalovirus in hematopoietic stem cell transplant recipients: prevention and therapy. Transplant infectious disease : an official journal of the Transplantation Society. 1999;1(3):165-78.
Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infectious disease clinics of North America. 2010;24(2):319-37.
Chemaly RF, Torres HA, Hachem RY, Nogueras GM, Aguilera EA, Younes A, et al. Cytomegalovirus pneumonia in patients with lymphoma. Cancer. 2005;104(6):1213-20.
Konoplev S, Champlin RE, Giralt S, Ueno NT, Khouri I, Raad I, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone marrow transplantation. 2001;27(8):877-81.
Ljungman P. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Seminars in respiratory infections. 1995;10(4):209-15.
Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2005;62(8 Suppl 1):S7-13.
Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Current infectious disease reports. 2012;14(6):633-41.
Bansal N, Arora A, Kumaran V, Mehta N, Varma V, Sharma P, et al. Atypical Presentation of Cytomegalovirus Infection in a Liver Transplant Patient. Journal of Clinical and Experimental Hepatology. 2011;1(3):207-9.
Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: Updates on clinical management. World Journal of Gastroenterology : WJG. 2014;20(31):10658-67.
Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2009;9 Suppl 4:S78-86.
Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, et al. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. Journal of medical virology. 2013;85(5):893-8.
Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2006;12(1):112-6.
Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/receptortargeted prodrug design: Strategies for human and veterinary drug development. Adv Drug Deliv Rev 2004;56:1437-52.
Melendez DP, Razonable RR. Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus. Infection and Drug Resistance. 2015;8:269-77.
Watcharananan SP, Louhapanswat S, Chantratita W, Jirasiritham S, Sumethkul V. Cytomegalovirus viremia after kidney transplantation in Thailand: predictors of symptomatic infection and outcome. Transplant Proc. 2012;44(3):701-5.
Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. Journal of virology. 2011;85(20):10884-93.
Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (Letermovir) against herpesviruses and other human pathogenic viruses. Antimicrobial agents and chemotherapy. 2012;56(2):1135-7.
Verghese PS, Schleiss MR. Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent. Drugs of the future. 2013;38(5):291-8.
Letermovir: Drug information [Internet]. 2018 [cited 2018 Oct 28]. Available from: https://www.uptodate.com/contents/Letermovir-drug-information?source=history_widget.
Limaye A, Budde K, Humar A, Vincenti F, Kuypers D, Carroll R P. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA.2023;330(1):33–42.
Kropeit D, von Richter O, Stobernack HP, Rubsamen-Schaeff H, Zimmermann H. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. Clinical pharmacology in drug development. 2018;7(1):9-21.
Stoelben S, Arns W, Renders L, Hummel J, Muhlfeld A, Stangl M, et al. Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with Letermovir: results of a Phase 2a study. Transplant international : official journal of the European Society for Organ Transplantation. 2014;27(1):77-86.
Patel R, Smith TF, Espy M, Portela D, Wiesner RH, Krom RA, et al. A prospective comparison of molecular diagnostic techniques for the early detection of cytomegalovirus in liver transplant recipients. The Journal of infectious diseases. 1995;171(4):1010-4.
Randhawa PS, Manez R, Frye B, Ehrlich GD. Circulating immediate-early mRNA in patients with cytomegalovirus infections after solid organ transplantation. The Journal of infectious diseases. 1994;170(5):1264-7.
Razonable RR, Brown RA, Wilson J, Groettum C, Kremers W, Espy M, et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation. 2002;73(6):968-73.
Marchetti S, Santangelo R, Manzara S, D'Onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. The new microbiologica. 2011;34(2):157-64.
Niubo J, Perez JL, Martinez-Lacasa JT, Garcia A, Roca J, Fabregat J, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagnostic microbiology and infectious disease. 1996;24(1):19-24.
Lo CY, Ho KN, Yuen KY, Lui SL, Li FK, Chan TM, et al. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay. Clinical transplantation. 1997;11(4):286-93.
Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80(5):1358-64.
The TH, van der Ploeg M, van den Berg AP, Vlieger AM, DER GIESSEN MV, VAN SON WJ. DIRECT DETECTION OF CYTOMEGALOVIRUS IN PERIPHERAL BLOOD LEUKOCYTES-A REVIEW OF THE ANTIGENEMIA ASSAY AND POLYMERASE CHAIN REACTION. Transplantation. 1992;54(2):193-8.
Schafer P, Tenschert W, Gutensohn K, Laufs R. Minimal effect of delayed sample processing on results of quantitative PCR for cytomegalovirus DNA in leukocytes compared to results of an antigenemia assay. J Clin Microbiol. 1997;35(3):741-4.
Razonable RR, Paya CV, Smith TF. Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant Recipients. Journal of Clinical Microbiology. 2002;40(3):746.
Landini MP, Lazzarotto T, Maine GT, Ripalti A, Flanders R. Recombinant mono- and polyantigens to detect cytomegalovirus-specific immunoglobulin M in human sera by enzyme immunoassay. J Clin Microbiol. 1995;33(10):2535-42.
Halling VW, Maine GT, Groettum CM, Wilson JA, Spesard J, Brojanac S, et al. Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. Transplantation. 2001;71(3):395-7.
BMJ Best Practice cytomegalovirus infection [Internet]. 2023 [cited 2023 Dec 10]. Available from: https://bestpractice.bmj.com/topics/en-us/560/pdf/560.pdf.
Ramanan P, Razonable RR. Cytomegal`ovirus Infections in Solid Organ Transplantation: A Review. Infection & Chemotherapy. 2013;45(3):260-71.
Downloads
Published
Versions
- 2024-05-18 (2)
- 2024-05-01 (1)
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี